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Summary
  Increasing evidence suggests that not only ammonia, but also its alkyl-derivatives, including methyl-
amine, may modulate neuron fi ring. Methylamine occurs endogenously from amine catabolism and 
its tissue levels increase in some pathological conditions, including diabetes. Interestingly, methyl-
amine and ammonia levels are reciprocally controlled by a semicarbazide-sensitive amine oxidase 
activity that deaminates methylamine to formaldehyde with the production of ammonia and hydro-
gen peroxide. As already described for ammonia, methylamine also targets the voltage-operated 
neuronal potassium channels, probably inducing release of neurotransmitter(s). From this inter-
action it has been observed that methylamine is 1) hypophagic in mice without producing amphet-
amine-like effects and 2) a stimulator of nitric oxide release from rat hypothalamus. Methylamine 
hypophagia is also maintained in genetically obese and diabetic mice and is increased when these 
animals are pre-treated with a-amino guanidine, an inhibitor of methylamine oxidative deamina-
tion. The effect of a-amino guanidine suggests a potential benefi cial effect of this drug, and oth-
er such inhibitors, in controlling food intake in animals with disturbed eating behavior. Moreover, 
the activity of methylamine as an inducer of NO release suggests a role for the amine and for the 
enzymatic activity that degrades it in neurodegenerative diseases.
 key words: semicarbazide-senstitive amine oxidase activity • methylamine • ammonia • nitric oxide • 
potassium channels • hypophagia
 Full-text PDF: http://www.medscimonit.com/fulltxt.php?IDMAN=6503
 Word count: 2228
 Tables: 1
 Figures: 1
 References: 28
 Author’s address: Laura Raimondi, Dept. of Pharmacology, Viale G. Pieraccini, 6 50139 Florence, Italy, 
e-mail: laura.raimondi@unifi .it
Received: 2004.10.15
Accepted: 2005.03.15
Published: 2005.08.01
RA257
Review Article
WWW.MEDSCIMONIT.COM© Med Sci Monit, 2005; 11(8): RA257-261
PMID: 16049393
RA
Current Contents/Clinical Medicine • SCI Expanded • ISI Alerting System • Index Medicus/MEDLINE • EMBASE/Excerpta Medica • Chemical Abstracts • Index Copernicus
Electronic PDF security powered by ISL-science.com
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
PE
RS
ON
AL
 U
SE
ON
LY
BACKGROUND
Methylamine (MET) is, after ammonia (NH4
+), the simplest 
primary amine found in the body which results from endog-
enous, exogenous, or dietary sources. It is actively metabo-
lized through oxidative deamination carried out by the ben-
zylamine oxidase activity (Bz-SSAO), an enzyme belonging 
to the semicarbazide-sensitive amine oxidase class (SSAO; 
EC 1.4.3.6), for which a soluble and a membrane-bound iso-
form have been described. Membrane-bound Bz-SSAO is 
highly expressed in adipocytes [1] and smooth muscle cell 
membranes [2], from which it derives the truncated iso-
form found circulating in some pathological conditions [3]. 
Both the membrane-bound and the soluble enzyme share 
high homology with the vascular adhesion protein VAP-1, a 
protein involved in lymphocyte-endothelium adhesion [4]. 
From this, the nomenclature of the enzyme can be updated 
to Bz-SSAO/VAP-1. The Bz-SSAO/VAP-1 deaminating activ-
ity transforms MET to formaldehyde with the production of 
hydrogen peroxide and NH4
+. This enzyme exerts a crucial 
role in controlling the reciprocal levels of NH4
+ and MET at 
the site of its catalysis. While the cellular and metabolic im-
pact of Bz-SSAO/VAP-1-dependent MET oxidation in gen-
erating H2O2 and formaldehyde has been extensively stud-
ied [5], less attention has been focused on Bz-SSAO/VAP-1 
in modulating MET and NH4
+ endogenous levels at differ-
ent physio/pathological conditions characterized by altered 
concentrations of these basic compounds [6,7].
As already postulated for NH4
+, MET may alter exocytotic 
activity of excitable cells mainly through two mechanisms: 
intravesicular alkalinization [8] or a block of different po-
tassium currents in pre- or post-synaptic membranes [9]. 
From both these mechanisms, changes in animal behavior 
and/or neurological functions can be observed as a con-
sequence of neurotransmitter release [10]. For NH4
+, the 
ability to induce a blockage of voltage-operated potassium 
channels, thus producing the release of g-aminobutyrric 
acid (GABA), glutamate, taurine, and nitric oxide (NO), 
has already been demonstrated, as well as changes in ani-
mal behavior [11,12].
Little indirect information is available on MET tissue and 
plasma levels and on its physiological role(s) in rodents 
and humans [13,14]. It is known that MET plasma and uri-
nary levels increase following Bz-SSAO/VAP-1 inhibition 
[6] or in some pathological conditions such as diabetes, 
typhoid fever, and liver or renal insuffi ciency [15]. In par-
allel, in the plasma of diabetic patients [16] as well as in 
the plasma of animal models of type I or type II diabetes 
[17], Bz-SSAO/VAP-1 levels also increased, a fi nding that 
has aroused interest in the role of the enzyme and its sub-
strate in diabetes. In this respect, recent data confi rm that 
Bz-SSAO/VAP-1 catalysis generates and sustains the diabe-
tes vascular complications, a fi nding in contrast to the op-
posite (benefi cial) insulin-like effects of the H2O2 produced 
by MET degradation [18,19]. This latter fi nding makes the 
relationship between Bz-SSAO/VAP-1 activity and substrate 
concentration quite puzzling and underlines the need to 
explore MET (and NH4
+) physiological role(s) in rodents 
and humans. All together, these results strongly support the 
view that the physiological signifi cance of Bz-SSAO/VAP-1 
can be better elucidated by improving our knowledge of the 
physiological role of its substrates and reaction end-prod-
ucts. The role of tissue and plasma MET levels in modulat-
ing central neurotransmitter release (as NH4
+ does) has not 
yet been clarifi ed.
THE ROLE OF METHYLAMINE IN THE CENTRAL NERVOUS 
SYSTEM
Recent data have shown that MET is able to interfere with 
the hypothalamic system involved in regulating food intake 
of fasted mice [20]. Feeding is a complex behavioral func-
tion in mammals, controlled by a network of hormones, 
peptides, and neurotransmitters, with anorexic and orexic 
signaling features whose reciprocal concentrations fl uctu-
ate at the hypothalamus. During fasting, this physiological 
clock shifts towards increasing levels of orexic mediators 
[21]. In fasted animals, MET, delivered intraperitoneally 
(i.p.) or directly into the central nervous system (i.c.v.), re-
duced, dose-dependently, food intake of healthy Swiss mice 
(i.p. EC50 = 334.6 mg/kg) without altering their locomo-
tor and exploring activity. MET potency was improved when 
the amine was administered at the time of Bz-SSAO/VAP-1 
inhibition [20].
a) What is the mediator involved in MET hypophagia?
Pharmacological evidence obtained in mice pre-treated 
with monoamine oxidase activity (MAO A or MAO B) in-
hibitors [20,22], dopaminergic or serotoninergic antago-
nists, and from microdialysis experiments in freely moving 
rats (unpublished results) confi rm that MET did not evoke 
dopamine or serotonin release (both amines are MAO sub-
strates), thus excluding the possibility that MET might have 
amphetamine-like effects. Hence, one plausible candidate 
responsible for MET hypophagia might have a peptidergic 
or aminoacidergic moiety.
b) Methylamine hypophagia depends on neuronal 
potassium channels
It is well known that neuron fi ring can be modulated at dif-
ferent levels. One way of controlling neurotransmitter re-
lease is to modify the gating activity of ion channels, among 
which are the potassium channels. MET hypophagia was 
reduced when the expression of the isoform Kv1.6 of the 
“Shaker-like” family (Kv1-7) was down-regulated by using 
a selective antisense oligodeoxyribonucleotide (aODN6). 
Interestingly, the reduced expression of the Kv1.6 reduced 
methylamine-dependent, but not ammonia-dependent hy-
pophagia (Figure 1). This result suggests that, despite the 
large similarities, ammonia and methylamine interact with 
different neuronal potassium channels. At present, lacking 
direct electrophysiological data, we hypothesize that MET 
might induce hypophagia by controlling the neuronal re-
lease of some neurotransmitter(s), similarly to that which 
was already described for known blockers of neuronal volt-
age-operated potassium channels [23].
c) Is methylamine hypophagia maintained in hyperphagic, 
obese animals over-expressing Bz-SSAO/VAP-1?
Obesity is considered an important risk factor for cardiovas-
cular diseases and for the onset of the metabolic syndrome. 
Both are consequences of bad life-style habits, typical of peo-
ple from industrialized countries. Obesity is the result of 
Review Article Med Sci Monit, 2005; 11(8): RA257-261
RA258
Electronic PDF security powered by ISL-science.com
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
Th
is
 c
op
y 
is
 fo
r 
pe
rs
on
al
 u
se
 o
nl
y 
- d
is
tr
ib
ut
io
n 
pr
oh
ib
it
ed
.  
   
PE
RS
ON
AL
 U
SE
ON
LY
an imbalance between energy intake and its expenditure. 
This complex ratio is regulated by a plethora of peripher-
al or central signals, such as leptin, which modulate the fi r-
ing of hypothalamic neurons, especially those located at the 
ventromedial hypothalamus and the arcuate nucleus [24]. 
Leptin is an adipocyte hormone which signals at the hypoth-
alamus to stop feeding and is a key component of the long-
term system which maintains body weight. Through the ac-
tivation of receptors, it negatively controls the release of 
NPY/agouti (two strong orexigen peptides), whereas it in-
creases the release of other anorexic mediators.
Obesity can be reproduced in animals in different ways, in-
cluding genetic manipulation. Rodents in which either the 
gene coding for leptin (ob/ob mice) or for its hypothalam-
ic receptor (db/db mice and fa/fa rats) have been silenced 
are obese (animals with overstimulation of feeding and re-
duced energy expenditure) and soon develop all the neu-
rological and behavioral signs of the insulin-resistance syn-
drome. Obese mice represent an important experimental 
model to verify whether MET hypophagia is maintained 
when the expression of its metabolizing activity (from adi-
pocytes and plasma) is high.
METHYLAMINE HYPOPHAGIA IN OBESE MICE
The hypophagic effect of MET was investigated in 4 month 
old C57Jdb/db (db/db) obese (and type II diabetic) mice 
and in their counterpart, lean animals (db/db+) bearing the 
heterozygous deletion of the leptin receptor. The charac-
teristics of the mice are shown in Table 1. Exogenous MET 
injected i.c.v. (30 and 75 µg), or i. p. (from 50 to 400 mg/
kg) produced a similar dose-dependent hypophagia in both 
obese and fasted lean mice, despite the fact that obese mice 
had higher levels of the Bz-SSAO/VAP-1 activity than the 
lean mice. Interestingly, in the adipose tissue of obese ani-
mals, the mRNA levels for Bz-SSAO/VAP-1 were lower than 
those measured in db/db+ (data not shown). This fi nding is 
an agreement with previous observations obtained in Zucker 
rats and supports the hypothesis that Bz-SSAO/VAP-1 activi-
ty may directly or indirectly control its mRNA levels (27). In 
contrast, no signifi cant differences were observed between 
db/db and db/db+ animals in the mRNA levels for brain 
Kv1.6 channels. Notably, brain Bz-SSAO/VAP-1 activity in 
db/db and db/db+ animals was clearly measurable.
a) The role of Bz-SSAO/VAP-1 in obese mice
The role of Bz-SSAO/VAP-1 in both animal strains in con-
trolling MET central levels was estimated using animals 
pre-treated with a-amino guanidine (a-AMG; 50 mg/kg 
i.p.). Under these experimental settings, an increase in 
MET (i.p) hypophagic potency was observed only in the 
obese and not in the lean ones (EC50 was shifted signifi -
cantly to the left), whereas in both animal strains the a-AMG 
treatment produced a signifi cant potentiation of MET hy-
pophagia when it was injected i. c. v. These results allow the 
conclusions that 1) C57BL animals were more sensitive to 
MET hypophagia than Swiss albino mice, 2) the increase 
in MET potency in db/db mice after a-AMG, mirrors the 
higher availability of the Bz-SSAO/VAP-1 in obese animals, 
3) brain Bz-SSAO/VAP-1 has a signifi cant role in controlling 
MET central levels in both animal strains, 4) the leptin cir-
cuit is not involved in MET hypophagia, and 5) the effect 
of a-AMG on the potentiation of MET hypophagia might 
be an aspect of the benefi cial effects reported for the drug 
in diabetes. Moreover, since MET and Bz-SSAO/VAP-1 lev-
els increased in diabetes, this high MET metabolizing ac-
tivity might account, at least partially, for the hyperphagia 
which characterize the diabetic animals.
METHYLAMINE AND NITRIC OXIDE: A FURTHER INTERPLAY 
BETWEEN THE AMINE AND POTASSIUM CHANNELS
Recent experiments show that MET increases NO levels in 
the hypothalamus. In fasted rats, at doses that do not affect 
food consumption, MET (5 and 15 µg injected i.c.v.) pro-
duces a time-dependent increase in NO (from 0.2 to 1 µM 
in microdialysate samples from hypothalamus. This effect 
Saline NH 3 MET DMA TMA
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Figure 1.  The hypophagic eff ects of methylamine, dimethyl, and 
trimethyl amine are selectively abolished by knocking 
down neuronal Kv.1.6 expression. Mice were injected 
i.c.v. with dODN and aODN (9 nmol per single injection on 
days 1, 4, and 7). Mice were starved overnight and drugs 
were injected i.c.v. (5 ml) under light anesthesia. Food 
consumed by each mice was evaluated for 60 min after drug 
administration.
db/db+ db/db
Body weight (g)  30.7±0.6  53.1±2.9
Epidydimal fat (g)
(% of body eight)  1.2±0.2  4.8±0.7
Plasma glycemia (mM) 10 >20
Adipose tissue Bz-SSAO 
activity (nmoles/g/15 min)  11.2±0.1  25.5±0.7*
Table 1.  Some metabolic characteristics of 4 month old db/db and 
db/db+ mice.
Animals were fasted overnight and sacrifi ced. Plasma glycemia 
was evaluated spectrophotometrically (Sigma-Aldrich). Bz-SSAO 
activity of white adipose tissue was evaluated radiochemically using 
14C-benzylamine (50 µM) as substrate. (*Signifi cantly diff erent from 
the db/db+, p<0.05).
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was antagonized by L-NAME (2 µmol, i.c.v.) and it was also 
signifi cantly reduced (–52.7%) in animals bearing the ex-
pression of potassium channel (Kv1.6) knocked down by 
pretreatment with a selective aODN. These preliminary re-
sults provide the fi rst evidence that MET, by interacting with 
Kv1.6 channels, induces the release of non-monoaminergic 
mediators in the brain. Moreover, because an NO-releasing 
activity was also described as a sequential mechanism dur-
ing acute ammonia neurotoxicity (28), the present data 
support the view that MET could take place, with NH4
+, in 
central neurodegenerative pathologies.
METHYLAMINE AND OTHER ALKYL-AMINES
In addition to NH4
+ and MET, dimethyl and trimethylamine 
(DMA and TMA) and trimethyl amine (TMA) also occur 
endogenously at low concentrations as the end-products of 
nitrogen metabolism. Interestingly, DMA is produced by the 
degradation of nitro arginine derivatives, among which is 
the asymmetric dimethyl arginine (ADMA), the most po-
tent endogenous inhibitor of NO synthase activity. ADMA is 
degraded by a dimethyl arginine dimethyl amino hydrolase 
activity (EC 3.5.3.18), producing citrulline and DMA.
We have verifi ed that DMA and TMA still maintain the hy-
pophagic effect of MET and NH4
+ described in healthy fasting 
mice. As it occurred for MET, DMA and TMA hypophagia was 
still dependent on Kv1.6 expression, whereas NH4
+ hypophagia 
was not (Figure 1). Unlike MET, TMA, and DMA are not re-
lated to Bz-SSAO/VAP-1 activity. Nothing is known yet about 
the ability of TMA and DMA to evoke NO release. If it were 
be found, a link between plasma and tissue levels of NO syn-
thase inhibitors (nitro arginines, ADMA) and of NO producers 
(short amines) might be postulated. This might represent an 
additional pathway in controlling NO availability, explaining 
vascular complications observed in several pathologies char-
acterized by nitrogen metabolic derangements [27].
CONCLUSIONS
MET and NH4
+, two short amines which are, respectively, 
a substrate and an end-product of Bz-SSAO/VAP-1 activity, 
have their own features in the central nervous system. The 
two amines, targeting at different neuronal voltage-oper-
ated potassium channels, induce both reduction of food 
intake and also the release of NO [28], a fi nding which 
opens new perspectives in the study of the physio/path-
ological role of MET, with particular regard to neurode-
generative pathologies where short-amine central levels in-
crease. Pharmacological modulation of MET, and then of 
ammonia central levels, can be achieved by using a-AMG, a 
Bz-SSAO/VAP-1 inhibitor, a strategy that could play an im-
portant role in controlling food intake and weight gain in 
obese animals without inducing amphetamine-like effects.
The substitution of an ammonia hydrogen(s) with a methyl 
group(s) (from MET to DMA and TMA) appears to be a con-
dition for distinguishing the type of neuronal Kv1.6 chan-
nels blocked. Despite this chemical selectivity, MET, DMA 
TMA, and NH4
+ are all hypophagic, and MET and NH4
+ re-
lease NO at hypothalamic nuclei.
The evidence suggests that 1) Bz-SSAO/VAP-1 activity is es-
sential in controlling hypophagic mediator levels in the cen-
tral nervous system, 2) there is a link between the NO path-
way and Bz-SSAO/VAP-1 activity, and 3) small alkyl derivatives 
of NH4
+ might be included among other important known 
endogenous modulators of tissue and cell functions.
The monitoring of the tissue levels of these short amines is 
now the fi rst-line aim of future investigations in this fi eld.
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